scopemd
arrow_backBack to tools

Analgesia

Opioid Ramp & Taper Helper

Use your patient's current opioid regimen and 24-hour MME to plan cautious dose increases or tapers. The tool shows its math and nudges toward multimodal analgesia; it does not replace clinical judgment or local policies.
  • Physician-developed
  • Transparent calculations
  • References provided
This tool is a dose-planning aid and does not replace clinical judgement. Always verify calculations and consider patient-specific factors.
Ramp & taper plannerPlan stepwise dose changes from the current regimenMulti-step

01 · Baseline

Paste current regimen

Start from a reconciled regimen or a known 24-hour MME. Uncertain fields stay visible for confirmation.

Paste inpatient opioid regimen

Paste PHI-free medication list directly into text-box or select 'enter manually' to add meds using a drop-down menu.

OME breakdown
  • Tylenol/day: 0 mg
Dosing equivalents (reference)
AgentPO doseIV dose
Morphine30 mg10 mg
Hydromorphone7.5 mg1.5 mg
Oxymorphone10 mg1 mg
Meperidine300 mg75 mg
Fentanyl—0.1 mg
Oxycodone20 mg—
Hydrocodone30 mg—
Codeine120 mg—

Conversion factors are adapted from commonly used opioid equivalence charts, including the SinaiEM Opioid Conversion Chart (see image). Always verify with your institution's preferred reference.

Total estimated OME:~0 mg/day
Calculated baseline~0 MME/dayRegimen statusNo agents entered yet

02 · Intent & pace

Choose the direction — then the pace

Set whether you're escalating or tapering, how well pain is controlled, and how aggressive you'd like the change to be.

Multimodal regimen in place?

Current setting: Moderate (≈20–35% increase)

+30%applied to total MME
Smaller changeLarger change

Most guidelines favor 5–20% changes per step; larger shifts may require closer monitoring.

03 · Dose trajectory

Preview the path before acting

The plan shows discrete reassessment points, not an automatic instruction. Each step is a decision point.

Enter a regimen or a manual 24-hr MME in the baseline panel to preview the dose trajectory.
DirectionIncrease 30%(factor ≈ 1.00)Proposed target—MME checkLower MME (demo)

04 · Plan & monitor

Review the suggested plan and its assumptions

The calculated target MME and, when a regimen is entered, per-drug suggested dose changes.

Caution

  • Regimen entered but 24-hr MME is ~0 mg/day. Check doses and frequencies.

Multimodal regimen is not marked as in place. When safe, consider non-opioid adjuncts (e.g., acetaminophen, NSAIDs, neuropathic agents, regional techniques, non-pharmacologic measures) rather than escalating opioids alone.

Show calculation details
  • Baseline MME from regimen: ~0 mg/day.
  • Effective baseline used for planning: ~0 mg/day (manual override if provided > 0).
  • Scaling factor based on mode and slider: 1.00.
  • Target MME ≈ base × factor = 0 × 1.00 ≈ 0 mg/day.
  • Each complete regimen row's dose is multiplied by the same factor, then rounded to a practical mg amount.
Show references & guidance

This tool is meant as a structured thinking aid and does not replace institutional policies, guidelines, or bedside clinical judgment.

Clinical information & methodologyMME factors, special conversions, safety checks, FAQs, and referencesExplore the methodology ↓

Clinical information

How this tool works—and where the numbers need context.

The complete methodology stays with the calculator, but a persistent navigator makes each topic immediately reachable.

01 · Overview

About this opioid ramp & taper planner

This tool plans stepwise opioid dose changes — escalation when pain is uncontrolled, tapering when the risk-benefit balance has shifted — starting from the patient's current 24-hour morphine milligram equivalents (MME). Each step is computed as an explicit percentage change with the math shown, so the plan you copy into the chart is one you can verify line by line.

Dose changes are where regimens drift into trouble: escalations stack faster than reassessment happens, and tapers fail when steps are too large or too rushed. The planner anchors both directions to guideline-scale step sizes and keeps multimodal analgesia in view, rather than treating opioid adjustment as the only lever.

02 · Method

How step sizes are calculated

The planner totals the current regimen's 24-hour MME (or takes a known MME directly), then applies your selected percentage change per step. Presets map to conservative, moderate, and larger adjustments, and the slider makes the exact percentage explicit — the resulting base → target MME math is displayed before any drug-level suggestion.

Most guidance favors changes of roughly 5–20% per step for tapers and modest, reassessed increments for escalation. Larger single steps are sometimes appropriate, but they demand closer monitoring — the tool flags aggressive settings rather than hiding them in a default.

03 · Tapering

How fast is it safe to taper?

Speed depends on how long the patient has been on opioids. For long-term therapy, the CDC's 2022 guideline and the HHS tapering guidance favor slow tapers — on the order of 10% per month for patients on opioids for a year or more — while shorter courses can often tolerate 10% per week or faster. Abrupt discontinuation is the failure mode to avoid: it risks severe withdrawal, pain crisis, psychological distress, and transition to illicit sources.

A taper is not a one-way conveyor. Pauses are legitimate; so is holding at a plateau when function is stable. Reassess at every step, and remember that after even a brief taper, lost tolerance means a return to the previous dose can now be an overdose.

04 · Escalation

Ramping up without overshooting

When pain is uncontrolled, the instinct is a big jump; the safer pattern is a defined increment with a defined reassessment. The planner applies your chosen percentage to the current MME and shows the new daily total, so escalations stay deliberate. As totals approach or exceed 50 MME/day, weigh benefits against rising overdose risk, consider offering naloxone, and re-examine whether non-opioid adjuncts are actually optimized before the next step.

05 · Built-in guardrails

Safety checks this tool applies

01Running 24-hour MME total as the anchor for every step, shown before drug-level changes02Guideline-scale step presets, with aggressive settings flagged rather than defaulted03Escalating caution prompts as totals approach and exceed 50 MME/day04Multimodal and non-opioid adjunct reminders alongside every plan05Transparent base → target math you can verify against your own reference

06 · Frequently asked questions

Frequently asked questions

How fast should I taper a patient off opioids?

It depends on the duration of therapy. Patients on opioids for a year or more generally need slow tapers — around 10% per month per HHS/CDC guidance — while shorter courses may tolerate 10% per week or faster. Individualize, reassess at each step, and avoid abrupt discontinuation.

What if pain flares in the middle of a taper?

Pause rather than abandon. Holding at the current step (or briefly stepping back one increment) while optimizing non-opioid and non-pharmacologic strategies is an expected part of tapering, not a failure. A flare is also a moment to revisit the underlying pain generator.

Do short courses need a formal taper?

Courses under roughly one to two weeks usually don't require a structured taper in opioid-naïve patients. Beyond a few weeks of regular use, physical dependence is common enough that stepping down beats stopping abruptly.

What withdrawal symptoms should I warn patients about?

Anxiety, restlessness, sweating, rhinorrhea, gooseflesh, myalgias, abdominal cramping, diarrhea, and insomnia — uncomfortable but rarely dangerous in otherwise healthy adults. Severe symptoms suggest the taper step was too large; adjunct medications (e.g. alpha-2 agonists per local protocol) and a slower schedule help.

Why does a taper change overdose risk?

Tolerance fades within days to weeks of a dose reduction. If a patient returns to their previous dose after a partial taper — or resumes after stopping — the same milligrams now carry a much higher overdose risk. This is a core counseling point, and a reason to consider naloxone during and after any taper.

Does this planner replace clinical judgment?

No. Step percentages are population-scale conventions, not patient-specific prescriptions. Duration of therapy, psychiatric comorbidity, opioid use disorder risk, pain trajectory, and patient goals all shape the right schedule — the planner keeps the arithmetic honest while you make those calls.

07 · Sources

References

  1. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. MMWR Recomm Rep. 2022;71(3):1–95.
  2. U.S. Department of Health and Human Services. HHS Guide for Clinicians on the Appropriate Dosage Reduction or Discontinuation of Long-Term Opioid Analgesics. 2019.
  3. CDC. Pocket guide: tapering opioids for chronic pain.
  4. Fine PG, Portenoy RK. Establishing 'best practices' for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage. 2009;38(3):418–425.

Created and maintained by Yasmine Abbey, MD, MSc · Last reviewed:

Educational decision-support for clinicians. Not medical advice — verify all outputs against your clinical judgment, institutional protocols, and current guidelines.